Kane Biotech Inc. (KNBIF)
OTCMKTS · Delayed Price · Currency is USD
0.0290
-0.0035 (-10.77%)
Feb 12, 2026, 11:21 AM EST
Kane Biotech Revenue
Kane Biotech had revenue of 8.50K CAD in the quarter ending September 30, 2025, a decrease of -99.34%. This brings the company's revenue in the last twelve months to 574.87K, down -71.44% year-over-year. In the year 2024, Kane Biotech had annual revenue of 2.08M with 1,296.75% growth.
Revenue (ttm)
574.87K CAD
Revenue Growth
-71.44%
P/S Ratio
12.95
Revenue / Employee
n/a
Employees
n/a
Market Cap
5.35M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.08M | 1.93M | 1,296.75% |
| Dec 31, 2023 | 148.98K | -7.75K | -4.95% |
| Dec 31, 2022 | 156.73K | -1.45M | -90.25% |
| Dec 31, 2021 | 1.61M | 266.20K | 19.84% |
| Dec 31, 2020 | 1.34M | -351.95K | -20.78% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| LakeShore Biopharma | 84.75M |
| Vaccinex | 601.00K |
| GPL Holdings | 376.54K |
| AXIM Biotechnologies | 92.90K |
| Enzon Pharmaceuticals | 26.00K |
Kane Biotech News
- 2 months ago - Kane Biotech Announces Closing of Private Placement Offering with an Insider of the Company - GlobeNewsWire
- 2 months ago - Kane Biotech Presents New Data at Innovations in Wound Healing Annual Meeting - GlobeNewsWire
- 2 months ago - Kane Biotech Wins Approval For Revyve Antimicrobial Wound Gel Spray In Canada - Nasdaq
- 2 months ago - Kane Biotech Announces Third Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Kane Biotech Announces $800K Private Placement To Advance Wound Care Portfolio - Nasdaq
- 2 months ago - Kane Biotech Announces New Private Placement Offering - GlobeNewsWire
- 3 months ago - Kane Biotech Presents revyve® Data at Diabetic Foot and Southern Region Burn Conferences - GlobeNewsWire
- 5 months ago - Kane Biotech Completes U.S. FDA 510(k) Submission for revyve® Antimicrobial Wound Cleanser - GlobeNewsWire